Poor investigator brochures: Resarchers ca...Human drug trials are compromised by poor reporting and potential bias of animal research. German researchers analysed more than 700 preclinical animal studies and investigator brochures provided by … more ➔
Ose and Boehringer ink €1.1bn deal in im...French Ose Immunotherapeutics SA has licenced global commercialisation rights of its preclinical programme OSE-172 to Boehringer Ingelheim which hopes to complement its immunoncology portfolio … more ➔
Cellectis in offering of US$175m ADS follo...French allogenic CAR-T cell therapy developer Cellectis is set to launch an underwritten public offering of $175m of its American Depositary Shares (ADS), each representing one ordinary share of … more ➔
Motif Bio to submit NDA for iclaprim Motif Bio has initiated a NDA rolling submission for iclaprim, a Gram-positive-targeted investigational antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI) … more ➔
Takeda announced bid for Shire Japanese drug giant Takeda Pharmaceutical Co. Ltd. has confirmed its intention to make a bid for orphan drug leader and neurology specialist Shire plc. The take-over offer has to be made until 25 April. more ➔
Roche reports 5 deaths after dosing of Hem...Roche’s US arm Genentech has confirmed a total of 5 deaths in adult patients who were dosed with its to-be hemophilia blockbuster emicizumab (Hemlibra), a BITE antibody that mimics the effect … more ➔
From biorefineries to consumer goodsMore than 400 experts came together at the World Bio Market Conference in Amsterdam to discuss the challenges of successfully implementing bio-based business strategies. more ➔
Ablynx SLE antibody vobarilizumab miss e... Belgian nanobody maker Ablynx IL-6 receptor blocker vobarilizumab didnt met the primary endpoint of dose response at 24 weeks in a Phase II study enroling 312 patients with severe, active … more ➔
MorphoSys files registration for ADS offer...Antibody specialist MorphoSys AG has filed a Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission (SEC) for a proposed Nasdaq offering of American Depositary Shares (A … more ➔
Deinove to licence antibiotic leads form R...French antibiotics player Deinove has inked a licence option agreement with Redx Pharma plc concerning a new class of synthetic preclinical topoisomerase blockers to treat infections caused by Gram-negative … more ➔
